Evidence map›Paper›PMID 34342817›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

Long-term outcomes of spinal SBRT. Is it important to select the treatment time?

H Pérez-Montero, O Godino, A Lozano, L Asiáin, I Martínez, J J Sánchez, R de BlasFernández, E Fernández, M Stefanovic, N García and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

H Pérez-MonteroRadiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain.ORCID http://orcid.org/0000-0002-9756-5088
O GodinoNeurosurgery Department, Hospital Universitari de Bellvitge, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1004-6366
A LozanoRadiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain.ORCID http://orcid.org/0000-0003-0528-5212
L AsiáinRadiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6941-0575
I MartínezRadiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4682-8703
J J SánchezRadiodiagnostic Department, Hospital Universitari de Bellvitge, Barcelona, Spain.ORCID http://orcid.org/0000-0003-0677-3680
R de BlasFernándezMedical Physics and Radiation Protection Department, Institut Català D'Oncologia, Barcelona, Spain.ORCID http://orcid.org/0000-0002-0390-4334
E FernándezPhysical Medicine and Rehabilitation Department, Hospital Universitari de Bellvitge, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2081-8438
M StefanovicRadiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9293-4385
N GarcíaRadiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1379-0921
J MartínezRadiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain.
F GuedeaRadiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8798-8696
A Navarro-MartinRadiation Oncology Department, Institut Català D'Oncologia, Barcelona, Spain. anavarro@iconcologia.net.ORCID http://orcid.org/0000-0002-1327-5367

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSBRT (stereotactic body radiation therapy) is widely used as a curative treatment in tumoral lesions and has become a fundamental tool for the treatment of spine metastasis. In this study, we present survival and toxicity outcomes of spine SBRT after a 2-year follow-up. METHODS/PATIENTS: Data from spine SBRT treatments performed at our institution between March 2012 and February 2020 was collected. Medical records, including demographic, primary tumor, and treatment characteristics were reviewed. Patient follow-up included clinical evaluation, imaging, and blood tests. Toxicity was recorded according to CTCAE v4.0.

resultsWe analyzed 73 consecutive spine SBRT treatments in 60 patients. 39.7% of the cases had primary breast cancer and 23.3% had prostate cancer. Most cases (87.7%) were treated with a single SBRT fraction of 16 Gy. Median follow-up was 26.1 months (range 1.7-78.6), and 1- and 2-year overall survival (OS) rates were 96.9% and 84.2%, respectively. Local control (LC) rates at 1- and 2-years were 76.3% and 70.6%, respectively. Multivariate analysis identified histology as a prognostic factor for both OS and LC. Patients who underwent spine SBRT 6 months after the spinal lesion diagnosis had LC at 2 years of 88%, vs 61.7% for those who underwent SBRT before this period. No grade III or higher toxicity was reported. The vertebral compression fracture (VCF) rate was 4.1%.

conclusionSpine SBRT at our institution showed a 2-year LC of 70.6%, without G3 toxicities. Delaying SBRT at least 6 months to administer systemic treatment was related to an improvement in local control.

Indexed as

RadiosurgeryAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesSpinal NeoplasmsSurvival RateTime FactorsTime-to-TreatmentTreatment OutcomeBone metastasesSBRTSpinal metastasesSpineStereotactic body radiotherapyStereotactic radiosurgery

Identifiers

PMID34342817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.